Key Facts

Latest information about our company.

Global Business

Updated January 2017

Chief Executive Officer:
New York City
Web Address:
NYSE Listing:
Net Global Sales:
$19.4 billion in 2016
R&D Investment:
$4.94 billion which included the discovery and development of new medicines for patients
Principal Locations:

Local Business

Updated July 2017

Australian head office:
Level 2, 4 Nexus Court, Mulgrave, Victoria 3170, Australia
Key Products in Market:
BARACLUDE® (entecavir)
DAKLINZA™ (daclatasvir)
ELIQUIS® (apixaban)
EVOTAZ® (atazanavir & cobicistat)
OPDIVO® (nivolumab)
ORENCIA® (abatacept)
REYATAZ® (atazanavir sulfate)
SPRYCEL® (dasatinib)
SUNVEPRA® (asunaprevir)
YERVOY™ (ipilimumab)